Andrea Pfeifer (AC Immune)

AC Im­mune has 're­mark­able' Alzheimer's vac­cine da­ta. Just don't ask to see them

AC Im­mune an­nounced it has “re­mark­able,” “un­prece­dent­ed” re­sults on an Alzheimer’s vac­cine. You’re just not al­lowed to see the da­ta.

On Thurs­day, the J&J-part­nered Swiss biotech said that its vac­cine had gen­er­at­ed “high” lev­els of an­ti­bod­ies against tau, a tan­gled pro­tein com­mon­ly im­pli­cat­ed in Alzheimer’s, in every pa­tient in their Phase I/II tri­al for the neu­rode­gen­er­a­tive dis­ease. The stock $ACIU in­stant­ly dou­bled in pre-mar­ket trad­ing, ris­ing from $7.30 to $14.70, and briefly mak­ing AC Im­mune once again a $1 bil­lion com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.